Cargando…
Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis
INTRODUCTION: Treatment with disease-modifying therapies (DMT) in patients with clinically isolated syndrome (CIS) represents standard care in multiple sclerosis (MS) patients nowadays. Since a proportion of patients may show no evidence of disease activity (NEDA) after some time of treatment, the q...
Autores principales: | Monschein, Tobias, Salhofer-Polanyi, Sabine, Altmann, Patrick, Zrzavy, Tobias, Dal-Bianco, Assunta, Bsteh, Gabriel, Rommer, Paulus, Berger, Thomas, Leutmezer, Fritz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990829/ https://www.ncbi.nlm.nih.gov/pubmed/32929591 http://dx.doi.org/10.1007/s00415-020-10074-4 |
Ejemplares similares
-
Feasibility of a smartphone app to monitor patient reported outcomes
in multiple sclerosis: The haMSter interventional trial
por: Altmann, Patrick, et al.
Publicado: (2022) -
Predisposing Factors for Sexual Dysfunction in Multiple Sclerosis
por: Altmann, Patrick, et al.
Publicado: (2021) -
The Smartphone App haMSter for Tracking Patient-Reported Outcomes in People With Multiple Sclerosis: Protocol for a Pilot Study
por: Altmann, Patrick, et al.
Publicado: (2021) -
Peripheral Hemolysis in Relation to Iron Rim Presence and Brain Volume in Multiple Sclerosis
por: Krajnc, Nik, et al.
Publicado: (2022) -
Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023)